281 related articles for article (PubMed ID: 31912328)
21. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
[TBL] [Abstract][Full Text] [Related]
22. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Ghazi M; Roux C
Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
[TBL] [Abstract][Full Text] [Related]
23. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
24. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
[TBL] [Abstract][Full Text] [Related]
25. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
[TBL] [Abstract][Full Text] [Related]
26. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
28. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
30. Osteoporosis management in patients with breast cancer: EMAS position statement.
Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Rhee Y; Song K; Park S; Park HS; Lim SK; Park BW
Endocr J; 2013; 60(2):167-72. PubMed ID: 23064476
[TBL] [Abstract][Full Text] [Related]
32. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Berruti A; Tucci M; Mosca A; Vana F; Ardine M; Dogliotti L; Angeli A; Bertoldo F
J Clin Oncol; 2007 Apr; 25(11):1455-6. PubMed ID: 17416873
[No Abstract] [Full Text] [Related]
33. Identification of osteopenic women at high risk of fracture: the OFELY study.
Sornay-Rendu E; Munoz F; Garnero P; Duboeuf F; Delmas PD
J Bone Miner Res; 2005 Oct; 20(10):1813-9. PubMed ID: 16160738
[TBL] [Abstract][Full Text] [Related]
34. Increased fracture rate in women with breast cancer: a review of the hidden risk.
Body JJ
BMC Cancer; 2011 Aug; 11():384. PubMed ID: 21875433
[TBL] [Abstract][Full Text] [Related]
35. Bayesian synthesis using prior information on fracture risk from randomized trials to analyze post-market data.
John-Baptiste A; Becker T; Fung K; Lipscombe LL; Austin PC; Anderson GM
J Clin Epidemiol; 2018 Sep; 101():79-86. PubMed ID: 29879465
[TBL] [Abstract][Full Text] [Related]
36. Fracture incidence after 3 years of aromatase inhibitor therapy.
Bouvard B; Soulié P; Hoppé E; Georgin-Mege M; Royer M; Mesgouez-Nebout N; Lassalle C; Cellier P; Jadaud E; Abadie-Lacourtoisie S; Tuchais C; Vinchon-Petit S; Audran M; Chappard D; Legrand E
Ann Oncol; 2014 Apr; 25(4):843-847. PubMed ID: 24608193
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
38. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
[TBL] [Abstract][Full Text] [Related]
39. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women.
Morin SN; Lix LM; Leslie WD
J Bone Miner Res; 2014 Jul; 29(7):1675-80. PubMed ID: 24535832
[TBL] [Abstract][Full Text] [Related]
40. Aromatase inhibitors and bone health in women with breast cancer.
Chien AJ; Goss PE
J Clin Oncol; 2006 Nov; 24(33):5305-12. PubMed ID: 17114665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]